Previous 10 | Next 10 |
Gainers: Houston American Energy (HUSA) +245%.U.S. Energy (USEG) +167%.Greenpro Capital (GRNQ) +39%.Adial Pharmaceuticals (ADIL) +34%.Innodata (INOD) +33%.Digimarc (DMRC) +30%.VOC Energy Trust (VOC) +26%.New Concept Energy (GBR) +26%.Cardiff Oncology (CRDF) +22%.Novus Capital (...
Gainers: NanoVibronix (NAOV) +98%, AIM ImmunoTech (AIM) +29%, Rockwell Medical (RMTI) +22%, Aurora Cannabis (ACB) +16%, Allied Healthcare Products (AHPI) +15%.Losers: Vaccinex (VCNX) -56%, BioSig Technologies (BSGM) -30%, ADC Therape...
Gainers: Cubic (CUB) +30%.AcelRx Pharmaceuticals (ACRX) +23%.VerifyMe (VRME) +22%.Cardiff Oncology (CRDF) +19%.Roku (ROKU) +16%.Trinity Place (TPHS) +14%.Super League Gaming (SLGG) +12%.Humanigen (HGEN) +12%.CleanSpark (CLSK) +12%.MicroVision (MVIS) +11%.Losers: Condor Hospitality T...
Gainers: AcelRx Pharmaceuticals (ACRX) +17%, Cardiff Oncology (CRDF) +16%, Humanigen (HGEN) +14%, Medicenna Therapeutics (MDNA) +11%, Orgenesis (ORGS) +7%.Losers: iCAD (ICAD) -21%, Pieris Pharmaceuticals (PIRS) -19%, Legend Biot...
Gainers: Ebang International (NASDAQ: EBON ) +42% . More news on: Ebang International Holdings Inc., Cardiff Oncology, Inc., Herman Miller, Inc., Stocks on the move, , Read more ...
Cardiff Oncology rises ( CRDF +24.4% ) on clinical data that further demonstrates the safety, efficacy and durability of response of onvansertib in KRAS-mutated metastatic colorectal cancer (mCRC). Data were presented at the European Society of Medical Oncology Virtual Congress . M...
SAN DIEGO , Sept. 17, 2020 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF) , a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, castration-res...
Cardiff Oncology (NASDAQ: CRDF ) +1% to host a key opinion leader (KOL) call focused on KRAS-mutated colorectal cancer and highlighting data from its onvansertib Phase 1b/2 clinical trial, on September 23 at 11 am-12:30 pm EDT. More news on: Cardiff Oncology, Inc., Healthcare st...
SAN DIEGO , Sept. 15, 2020 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF) , a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, today announced that it will host a key opinion leader (KO...
SAN DIEGO , Sept. 14, 2020 /PRNewswire/ -- Cardiff Oncology, Inc. (Nasdaq: CRDF) , a clinical-stage oncology therapeutics company developing drugs to treat cancers with the greatest medical need for new treatment options, including KRAS-mutated colorectal cancer, castration-res...
News, Short Squeeze, Breakout and More Instantly...
Cardiff Oncology Inc. Company Name:
CRDF Stock Symbol:
NASDAQ Market:
Cardiff Oncology Inc. Website:
SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will present at two upcoming investor conferences in M...
- In RAS-mutated mCRC, clinical data from ONSEMBLE trial, and preclinical data presented at AACR, demonstrated strong efficacy signal in bev naïve patients and support ongoing first-line RAS-mutated mCRC lead program - - In RAS wild-type mCRC, preclinical data presented at AACR dem...